How to access Doptelet from Saudi Arabia, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi patient with chronic immune thrombocytopenia (ITP) that has had insufficient response to a prior therapy, or a patient with chronic liver disease (CLD)-associated thrombocytopenia scheduled for a procedure, may receive a prescription for Doptelet (avatrombopag) from their treating haematologist or hepatologist. Doptelet is FDA-approved in the United States and developed by Sobi (acquired from Dova Pharmaceuticals). It is an oral thrombopoietin (TPO) receptor agonist taken with food. Where Doptelet is not on a Saudi hospital formulary, a named-patient import pathway via the Saudi Food and Drug Authority (SFDA) is the legitimate route.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Doptelet is an oral tablet taken once daily (with food) for chronic ITP, or on a defined pre-procedural schedule for CLD-associated thrombocytopenia (once daily for 5 days with the procedure scheduled on day 10-13). Dosing in ITP is titrated to platelet response. Your treating physician confirms diagnosis, baseline platelet counts, prior therapy history, thromboembolic risk assessment, and the monitoring plan per FDA labeling.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Doptelet legally importable into Saudi Arabia?
Yes, through the Saudi Food and Drug Authority (SFDA) named-patient / special-import framework. The pathway allows a Saudi Arabia-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent registered alternative fits, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.
How the pathway works, step by step
- Consultation with your treating physician. Diagnosis, platelet history, prior therapy history, and clinical rationale.
- Pre-treatment workup. Baseline CBC, thromboembolic risk assessment per labeling.
- SFDA named-patient application. The physician or hospital pharmacy files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner.
- Shipment. Doptelet is an oral tablet with standard storage; shipment includes tamper-evident packaging and chain-of-custody documentation.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming chronic ITP or CLD-associated thrombocytopenia, platelet counts, prior therapies, and Doptelet as the indicated treatment
- Verification of their Saudi medical registration
- Patient identifier
- Baseline workup confirmation
- Planned dosing regimen and monitoring cadence
Reserve Meds provides a physician documentation kit that bundles the templates SFDA reviewers expect to see for TPO receptor agonists.
Costs and timing
Doptelet's US cash-pay drug-only reference price for a 30-day ITP supply sits in a broad indicative range of roughly USD 9,000-13,000 depending on dose; the pre-procedural CLD course (5 tablets) is priced as a short course. International logistics, SFDA documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. Indicative range.
Indicative timing for first dose after cohort intake opens is 7-14 days from the moment a complete application is submitted. Refills (for chronic ITP) ship on a rolling basis.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Doptelet specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for SFDA review.
- Logistics. Tamper-evident, internationally tracked shipment.
- Concierge case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation.
How does Doptelet compare to other TPO agonists? Doptelet is taken with food (a notable practical difference from some other oral TPO agonists that have fasting requirements). Your physician will weigh practical and clinical factors.
Is the CLD pre-procedural course short? Yes, a typical pre-procedural course is 5 daily doses with the procedure scheduled a few days after completion, per labeling.
Will private insurance cover this? Cash-pay is the default. Some Saudi insurers reimburse named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Recent regulatory and access news for Doptelet in Saudi Arabia
The Saudi Food and Drug Authority Notifications feed at sfda.gov.sa/regulations has not posted a Doptelet-specific registration notice over the last 12 months as of 2026-06-04. The SFDA Drug Registration database at sfda.gov.sa/drugs-list does not list Doptelet as a registered product. The Council of Cooperative Health Insurance (CCHI) at cchi.gov.sa has not added Doptelet to the Essential Drug List for compulsory cover. Sobi continues commercial rollout of avatrombopag across the GCC with no Saudi-specific licensing partnership announcement through Q1 2026. The Saudi Society of Hepatology and the Saudi Society of Hematology continue to position avatrombopag as a thrombocytopenia-pre-procedure option for chronic-liver-disease patients. We update this section on each case file at intake; the snapshot date governs.
Next step
For Doptelet coordination in Saudi Arabia, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.